Fulcrum Therapeutics Inc
NASDAQ:FULC
Income Statement
Earnings Waterfall
Fulcrum Therapeutics Inc
Revenue
|
2.8m
USD
|
Operating Expenses
|
-113.5m
USD
|
Operating Income
|
-110.7m
USD
|
Other Expenses
|
13.3m
USD
|
Net Income
|
-97.3m
USD
|
Income Statement
Fulcrum Therapeutics Inc
Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
3
+267%
|
5
+67%
|
9
+92%
|
13
+46%
|
15
+18%
|
18
+20%
|
19
+4%
|
17
-11%
|
14
-15%
|
11
-26%
|
6
-41%
|
4
-36%
|
3
-25%
|
3
-14%
|
3
+7%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(34)
|
(63)
|
(69)
|
(77)
|
(84)
|
(67)
|
(71)
|
(75)
|
(80)
|
(83)
|
(89)
|
(94)
|
(100)
|
(107)
|
(119)
|
(118)
|
(118)
|
(119)
|
(111)
|
(113)
|
(113)
|
|
Selling, General & Administrative |
(8)
|
(9)
|
(10)
|
(11)
|
(13)
|
(16)
|
(18)
|
(20)
|
(21)
|
(22)
|
(23)
|
(27)
|
(31)
|
(36)
|
(40)
|
(41)
|
(42)
|
(42)
|
(42)
|
(42)
|
(42)
|
|
Research & Development |
(25)
|
(54)
|
(59)
|
(66)
|
(71)
|
(51)
|
(53)
|
(55)
|
(59)
|
(61)
|
(66)
|
(67)
|
(70)
|
(71)
|
(79)
|
(77)
|
(77)
|
(76)
|
(69)
|
(71)
|
(72)
|
|
Operating Income |
(34)
N/A
|
(63)
-89%
|
(69)
-9%
|
(77)
-11%
|
(84)
-9%
|
(66)
+22%
|
(68)
-4%
|
(70)
-3%
|
(72)
-2%
|
(70)
+2%
|
(74)
-5%
|
(75)
-2%
|
(81)
-8%
|
(90)
-11%
|
(105)
-16%
|
(108)
-3%
|
(112)
-4%
|
(115)
-2%
|
(108)
+6%
|
(111)
-3%
|
(111)
+0%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
1
|
1
|
1
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
6
|
9
|
12
|
13
|
|
Pre-Tax Income |
(33)
N/A
|
(62)
-92%
|
(68)
-9%
|
(75)
-11%
|
(83)
-10%
|
(64)
+22%
|
(67)
-4%
|
(69)
-4%
|
(71)
-2%
|
(69)
+2%
|
(73)
-6%
|
(75)
-2%
|
(81)
-8%
|
(90)
-11%
|
(104)
-16%
|
(107)
-3%
|
(110)
-2%
|
(109)
+1%
|
(98)
+9%
|
(99)
0%
|
(97)
+1%
|
|
Net Income | ||||||||||||||||||||||
Income from Continuing Operations |
(33)
|
(62)
|
(68)
|
(75)
|
(83)
|
(64)
|
(67)
|
(69)
|
(71)
|
(69)
|
(73)
|
(75)
|
(81)
|
(90)
|
(104)
|
(107)
|
(110)
|
(109)
|
(98)
|
(99)
|
(97)
|
|
Net Income (Common) |
(39)
N/A
|
(71)
-82%
|
(79)
-11%
|
(85)
-8%
|
(90)
-5%
|
(68)
+24%
|
(68)
+1%
|
(69)
-2%
|
(71)
-2%
|
(69)
+2%
|
(73)
-6%
|
(75)
-2%
|
(81)
-8%
|
(90)
-11%
|
(104)
-16%
|
(107)
-3%
|
(110)
-2%
|
(109)
+1%
|
(98)
+9%
|
(99)
0%
|
(97)
+1%
|
|
EPS (Diluted) |
-1.76
N/A
|
-3.19
-81%
|
-3.53
-11%
|
-3.83
-8%
|
-3.96
-3%
|
-3.01
+24%
|
-2.83
+6%
|
-2.53
+11%
|
-2.79
-10%
|
-2.2
+21%
|
-2.24
-2%
|
-2.05
+8%
|
-2.29
-12%
|
-2.2
+4%
|
-2.54
-15%
|
-2.32
+9%
|
-2.44
-5%
|
-1.82
+25%
|
-1.59
+13%
|
-1.59
N/A
|
-1.59
N/A
|